Brief: Alphamab Oncology Announces KN035 (Envafolimab) Obtained Marketing Approval In China From NMPA
25/11/2021 14:57
Nov 25 (Reuters) - Alphamab Oncology 9966.HK :
* ANNOUNCES KN035 (ENVAFOLIMAB) OBTAINED MARKETING APPROVAL
IN
CHINA FROM NMPA
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)